Program
MR-130A-01
A development code. Also written as “MR-130A-01 Transdermal patch” and “MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)”.
Its studies are led by Viatris.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Viatris | 21 open or running | phase 2since May 8, 2023 | May 8, 2023 | Nov 30, 2026phase 2 · NCT07365904 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 8, 2023First study: phase 2 study in ContraceptionFirst studyNCT06048536 · 168 enrolled · Germany
- Sep 8, 2025Phase 2 study in ContraceptionNCT07365904 · 60 planned · Germany
Ahead
- Nov 30, 2026Primary completion: phase 2 study in ContraceptionNCT07365904
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07365904Contraception · Germany | 2 | Recruiting | Nov 30, 2026 | 60 |
| NCT06048536Contraception · Germany | 2 | Completed | Jan 18, 2024 | 168 |
How it is read
Names in the registry
- “MR-130A-01 Transdermal patch”, 4 entries
- “MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)”, 1 entry
Codes read as this program: MR130A01.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.